Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy – Xconomy
Xconomy |
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy
Xconomy Despite the early and in some cases stunning results produced by gene therapy treatments in handfuls of hemophilia patients, significant questions remain about their durability, safety, and how broadly they’ll be used if they are ultimately shown to work. Dimension Therapeutics’ gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but …Seeking Alpha Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD DisclosureMarket Exclusive Is Dimension Therapeutics Inc (DMTX)’s Fuel Running Low? The Stock Reaches Yearly Low TodayThe Randolph Guide StreetInsider.com all 9 news articles » |
Xconomy |
Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy
Xconomy Despite the early and in some cases stunning results produced by gene therapy treatments in handfuls of hemophilia patients, significant questions remain about their durability, safety, and how broadly they’ll be used if they are ultimately shown to work. Dimension Therapeutics’ gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but …Seeking Alpha Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD DisclosureMarket Exclusive Is Dimension Therapeutics Inc (DMTX)’s Fuel Running Low? The Stock Reaches Yearly Low TodayThe Randolph Guide StreetInsider.com all 9 news articles » |
Huntington’s Disease News |
Potential Huntington’s Disease Gene Therapy Granted Expedited Patent Review
Huntington’s Disease News A patent application for Vybion’s potential gene therapy for Huntington’s disease (HD) and other neurodegenerative conditions has been granted Track One status by the U.S. Patent and Trademark Office (USPTO). Patent applications are ordinarily reviewed … |
|
Gene therapy saves Emirati infant’s life
gulfnews.com Once there, a team of doctors arranged to treat the baby with gene therapy — a cutting-edge technique which sees defective genes replaced with working ones made in a laboratory. Over the course of a week, bone marrow cells were taken out of Khalifa … |
gulfnews.com |
Gene therapy saves Emirati infant’s life
gulfnews.com Once there, a team of doctors arranged to treat the baby with gene therapy — a cutting-edge technique which sees defective genes replaced with working ones made in a laboratory. Over the course of a week, bone marrow cells were taken out of Khalifa … Gene therapy gives Emirati boy with rare genetic disorder a second chanceThe National |
StockNewsUnion |
Dimension Therapeutics’ gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but …
Seeking Alpha Thinly traded micro cap Dimension Therapeutics (NASDAQ:DMTX) is off 33% premarket on increased volume in response to its announcement of interim results from a Phase 1/2 clinical trial assessing gene therapy candidate, Orphan Drug-tagged DTX101, … Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD DisclosureMarket Exclusive Is Dimension Therapeutics Inc (DMTX)’s Fuel Running Low? The Stock Reaches Yearly Low TodayThe Randolph Guide Form 8-K Dimension Therapeutics, For: Jan 31StreetInsider.com |